NCT07561983Not yet recruitingPhase 2
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
Tislelizumab Combined With Intravenous Chemotherapy and Bronchial Artery Chemoembolization as Conversion Therapy for Unresectable Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Phase II Trial (BEACON-Lung)
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
The goal of this phase 2 trial is to evaluate the efficacy and safety of tislelizumab combined with intravenous chemotherapy and bronchial artery chemoembolization (BACE) as conversion therapy for patients with initially unresectable stage IIIA-IIIB non-small cell lung cancer (NSCLC). The main questions it aims to answer are: * What is the 1-year event-free survival (EFS) rate with this treatment? * Can this treatment improve tumor response and the chance of curative-intent resection? * What adverse events occur during treatment? Participants will receive tislelizumab, intravenous chemotherapy, and BACE for up to 4 cycles. Tumor response and resectability will be evaluated by imaging and multidisciplinary team (MDT) assessment every 2 cycles. Participants who become resectable may undergo surgery followed by postoperative treatment per protocol. Participants who remain unresectable after 4 cycles will receive guideline-recommended chemoradiotherapy followed by tislelizumab consolidation. Regular follow-up will be performed for efficacy and safety assessment.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- First submitted
- 24 Apr 2026
- Start date
- 1 May 2026
- Primary completion date
- 31 Oct 2028
- Lead sponsor
- Sichuan Cancer Hospital and Research Institute
- Diseases
- Lung cancer
- NCT number
- NCT07561983
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 39
- From 1 May 2026 to the primary completion date, 31 Oct 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior local therapy for NSCLC, including radiotherapy or interventional therapy
- Major surgery requiring general anesthesia within 4 weeks before first dose
Other illness
- History of another malignancy within the past 5 years
- Active autoimmune disease or history of autoimmune disease requiring systemic treatment
- Known allergy to any study drug or excipient
- Interstitial lung disease, non-infectious pneumonitis, chronic obstructive pulmonary disease, or other uncontrolled systemic diseases judged to interfere with study treatment
- Severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral therapy, including active tuberculosis
- Any medical condition, alcohol or drug abuse, or dependence that may interfere with study treatment, interpretation of results, or increase treatment risk
- Psychiatric illness or history of psychotropic drug abuse that may compromise study participation
- Any condition judged by the investigator to make the patient unsuitable for the study
Lab values
- Known positive driver genomic alterations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and MET exon 14 skipping alterations
Other
- Distant organ metastasis
- Participation in another interventional therapeutic clinical study
Who the study is looking for
- Age 18 to 80 years
- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
- Newly diagnosed, previously untreated stage IIIA-IIIB NSCLC according to the 9th edition TNM staging system
- Initially unresectable disease as determined by multidisciplinary team (MDT) assessment
- At least 1 measurable intrapulmonary lesion according to RECIST version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Forced expiratory volume in the first second (FEV1) \> 1.0 L and \> 40% of predicted normal value
- Estimated life expectancy of at least 3 months
- Adequate organ function
- Willingness to provide tumor tissue for pathology, molecular testing, and PD-L1 assessment before enrollment
- Women of childbearing potential must have a negative pregnancy test within 72 hours before the first dose and agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab
- Men with partners of childbearing potential must agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab
- Ability to understand and willingness to sign a written informed consent form
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sichuan Cancer Hospital and Research Institute Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.